

Applicants : Virginia M. Litwin, et al.  
U.S. Serial No.: 09/891,062  
Filed : June 25, 2001  
Page 2

Please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 5 of this paper.

Applicants : Virginia M. Litwin, et al.  
U.S. Serial No.: 09/891,062  
Filed : June 25, 2001  
Page 3

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of the claims in the application.

In the Claims

Please amend as follows:

Claims 1-39 (Cancelled).

--40. (Amended) A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of a monoclonal antibody or portion thereof effective to (a) specifically inhibit 67% or greater of fusion of a CD4+ PM-1 cell to a HeLa cell expressing envelope glycoprotein from HIV-1<sub>JR-FL</sub>, and (b) inhibit 18% or less of fusion of a CD4+ SUP-T1 cell to a HeLa cell expressing envelope protein from HIV-1<sub>LAI</sub>, wherein the antibody (i) does not crossreact with HIV-1 envelope glycoprotein or CD4, (ii) reacts with an antigen on the surface of a PM-1 cell, and (iii) does not react with an antigen on the surface of a SUP-T1 cell, and (iv) is at least as active as monoclonal antibody PA-7 in inhibiting fusion as recited in (a) above and less active than monoclonal antibody PA-6 in inhibiting fusion as recited in (b) above, so as to thereby inhibit HIV-1 infection of the CD4+ cell.--

--41. (Previously presented) The method of claim 40, wherein the monoclonal antibody is a chimeric monoclonal antibody.--

--42. (Previously presented) The method of claim 40, wherein the monoclonal antibody is humanized.--

Applicants : Virginia M. Litwin, et al.  
U.S. Serial No.: 09/891,062  
Filed : June 25, 2001  
Page 4

--43. (Previously presented) The method of claim 40, wherein the monoclonal antibody is a human monoclonal antibody.--

--44. (Previously presented) The method of claim 40, wherein the portion of the monoclonal antibody is a single chain antibody or an antigen binding fragment.--

--45. (Previously presented) The method of claim 40, wherein the monoclonal antibody is labeled with a detectable marker.--

--46. (Previously presented) The method of claim 45, wherein the detectable marker is a radioactive isotope, enzyme, dye or biotin.--

--47. (Previously presented) The method of claim 40, wherein the CD4+ cell is present in the subject and the contacting is effected by administering the monoclonal antibody or portion thereof to the subject.--